AEON Biopharma Inc
AEON.WS
AEON.WS was delisted on the 26th of April, 2024.
40 hedge funds and large institutions have $851K invested in AEON Biopharma Inc in 2023 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 10 reducing their positions, and 9 closing their positions.
49% more capital invested
Capital invested by funds: $572K → $851K (+$279K)
5% less funds holding
Funds holding: 42 → 40 (-2)
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
50% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Shaolin Capital Management
Miami,
Florida
|
+$113K |
| 2 |
D.E. Shaw & Co
New York
|
+$17.2K |
| 3 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$7.59K |
| 4 |
LP
LMR Partners
London,
United Kingdom
|
+$7.09K |
| 5 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$4.62K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Segantii Capital Management
Hong Kong
|
-$118K |
| 2 |
Parallax Volatility Advisers
San Francisco,
California
|
-$65K |
| 3 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$48.5K |
| 4 |
KC
Kepos Capital
New York
|
-$14K |
| 5 |
SIM
Sandia Investment Management
Boston,
Massachusetts
|
-$13.8K |
AEON.WS Hedge Fund Activity: Q3 2023 in Review
40 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma Inc (AEON.WS) for Q3 2023, worth a combined $851K — up 49% from $572K a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of AEON.WS and 7 opened new positions — a net loss of 2 holders — while 10 trimmed existing stakes and 5 added.
The largest buyer was Shaolin Capital Management, opening a new position worth an estimated $113K. The largest seller was Segantii Capital Management, exiting entirely with an estimated $118K sold.
- 40 institutional investors held AEON Biopharma Inc (AEON.WS) as of Q3 2023, down from 42 in Q2 2023.
- Funds reported $851K of AEON Biopharma Inc stock for Q3 2023, up 49% quarter-over-quarter.
- 7 funds opened new AEON Biopharma Inc positions in Q3 2023 and 9 closed out, a net change of -2 holders.
- The largest AEON Biopharma Inc buyer in Q3 2023 was Shaolin Capital Management, an estimated $113K added.
- The largest AEON Biopharma Inc seller in Q3 2023 was Segantii Capital Management, an estimated $118K sold.
Based on aggregated 13F filings for Q3 2023.